Wülfing Felix, Schmidt-Wolf Gabriele, Cremer-Schaeffer Peter, Priebe Kathlen, Schoofs Nikola
Klinik für Psychiatrie und Psychotherapie, Charité Universitätsmedizin Berlin Campus Charite Mitte, Berlin, Germany.
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), Bonn.
Psychiatr Prax. 2024 Sep;51(6):315-320. doi: 10.1055/a-2296-1358. Epub 2024 May 15.
Since 2017 physicians in Germany can prescribe cannabis based medicines or medical cannabis with subsequent funding by the statutory health insurance system.
Physicians prescribing cannabinoid drugs were legally required to take part in a survey conducted by the Federal Institute for Drugs and Medical Devices. This study analyses data from 16.809 case reports that were collected from 30.3.2017 to 31.12.2021.
There were 5582 cases documenting the use of cannabinoid drugs in psychiatric disorders. More than half of the prescriptions were Dronabinol. 80% of the treatments concerned somatoform disorders. Most of the treatments for other psychiatric disorders also targeted pain. Doctors reported a positive effect on symptoms in at least 75% of the cases.
Most patients with psychiatric disorders received cannabinoid drugs for pain. The evidence from randomized controlled clinical trials for the use of cannabinoid drugs in psychiatric indications is weak.
自2017年起，德国医生可以开具基于大麻的药物或医用大麻，随后由法定医疗保险系统提供资金支持。
法律要求开具大麻素类药物的医生参与联邦药品和医疗器械研究所进行的一项调查。本研究分析了2017年3月30日至2021年12月31日期间收集的16809份病例报告的数据。
有5582例记录了大麻素类药物在精神疾病中的使用情况。超过一半的处方是屈大麻酚。80%的治疗涉及躯体形式障碍。其他精神疾病的大多数治疗也针对疼痛。医生报告称，至少75%的病例症状有积极改善。
大多数精神疾病患者接受大麻素类药物治疗疼痛。关于大麻素类药物用于精神疾病适应症的随机对照临床试验证据不足。
